Taltz ixekizumab biosimilar 2026 patent expiry development pipeline?

Why 2026 matters for ixekizumab biosimilars
The main patents covering Taltz (ixekizumab) are set to expire in 2026, which removes a key legal barrier that has protected Pfizer’s monopoly on this drug for plaque psoriasis and psoriatic arthritis. Once those patents expire, competitors can pursue biosimilar development without infringing on exclusivity rights.

Who’s already moving on the pipeline
Several biopharmaceutical firms have indicated intent to develop ixekizumab biosimilars, although specific names and timelines are not publicly disclosed yet. The patent landscape suggests that any biosimilar entrant would need to launch a full regulatory program before 2028‑2029.

What the regulatory path looks like
Biosimilar approval in the U.S. follows the Biologics Price Competition and Innovation Act (BPCIA). Developers must show high‑level similarity through analytical studies, then conduct non‑clinical and clinical trials focused on pharmacokinetics, safety, and immunogenicity. The typical pathway takes 5–7 years, after which the FDA can grant biosimilarity status.

How long until a biosimilar could reach the market
With a 2026 patent expiry, the earliest a biosimilar could be approved is around 2028‑2029, assuming a streamlined development schedule. Commercial launch could follow a year after approval, making 2030 the earliest realistic market entry.

Potential pricing impact
Biosimilars generally drive down prices by 20–30 % compared with the originator, but actual discounts depend on market penetration, payer contracts, and competition from other biologics (e.g., secukinumab, brodalumab).

What to watch for in the next few years
- FDA’s first ixekizumab biosimilar approval.
- Patent litigation outcomes that may delay entry.
- Payer policies on biologic substitution.
- Pricing negotiations and potential discounts.

---

Sources

[1] https://www.drugpatentwatch.com/patents/ixekizumab